Catalyst Pharmaceutical Partners Appoints Chief Medical Officer And Vice President Of Regulatory Operations
Dr. Gorodetzky has more than 43 years of experience in pharmacology, drug development, clinical trials and addiction medicine. From 1999 to 2005, Dr. Gorodetzky was employed by Quintiles, Inc. in a variety of management positions, including as a Vice President in the Medical and Scientific Services Department. While at Quintiles, he had extensive experience with designing, organizing and managing large multi-center clinical trials in a variety of central-nervous system (CNS) indications, abuse liability and substance abuse treatment.
Prior to joining Quintiles, from 1994 - 1998 Dr. Gorodetzky was a Vice President of Hoechst Marion Roussel, Inc. (formerly Marion Merrell Dow), serving as Global Head of CNS Development, Head of Clinical Research North America and North American Medical Advisor. Dr. Gorodetzky has been directly involved in the clinical development of vigabatrin since 1995, initially as the primary responsible development person at Hoechst Marion Roussel (HMR) (now Sanofi Aventis) and then as the primary development person at Quintiles working with HMR in the clinical development of vigabatrin. Prior to joining HMR, Dr. Gorodetzky was employed by several pharmaceutical companies in management positions, with an emphasis on developing smoking cessation therapies and antiepileptic drugs. From 1963 to 1984, Dr. Gorodetzky was on the staff at the National Institute on Drug Abuse, Addiction Research Center, serving in his last position as the final director of NIDA's Lexington facility. Additionally, for the last few years, Dr. Gorodetzky has been a Clinical Professor of Psychiatry at the University of Missouri - Kansas City, where he has participated as a co-principal investigator at the Kansas site of the NIDA Methamphetamine Clinical Trials Group.
Mr. Winship has worked in regulatory affairs in the healthcare industry for 30 years. From 2004 to 2005, Mr. Winship was Vice President - Quality Assurance and Regulatory Affairs for Argos Therapeutics, Inc., a biotechnology company developing immunotherapy treatments for cancer. Previously, Mr. Winship was employed by CEL-SCI Corp., a biotechnology company developing immune system based treatments, from 1998 to 2002 as Senior Vice President - Regulatory Affairs and Quality Assurance, and from 1994 through 1998 as Vice President - Regulatory Affairs and Quality Assurance. From 1988 to 1994, Mr. Winship was employed by Curative Technologies, Inc., a health-care company involved in the wound-healing market, first as director of regulatory and quality assurance and later as Vice President of Regulatory Affairs and Quality Assurance.
Patrick J. McEnany, Chief Executive Officer of Catalyst, stated: "We are pleased to have Charles and Doug join our team. Charles brings extensive clinical development experience to Catalyst, especially due to his historical involvement with the development of vigabatrin. Doug brings extensive regulatory experience to Catalyst, and will oversee all aspects of our regulatory, compliance, quality assurance and quality control."
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. Catalyst has been granted an exclusive worldwide license from Brookhaven National Laboratory to nine U.S. patents and two U.S. patent applications relating to the use of vigabatrin for the treatment of a wide variety of substance abuses. Catalyst's product development efforts are currently focused on the development of CPP-109, its product candidate based on vigabatrin, as a treatment for cocaine and methamphetamine addiction. Visit Catalyst Pharmaceutical Partners, Inc. online at www.catalystpharma.com.
Source: Catalyst Pharmaceutical Partners, Inc.